Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) - Total Liabilities

Latest as of June 2026: $3.66 Billion USD

Based on the latest financial reports, Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) has total liabilities worth $3.66 Billion USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Amneal Pharmaceuticals, Inc. Class A Com strategic investment ratio to see how much of total assets are deployed in long-term investments.

Amneal Pharmaceuticals, Inc. Class A Common Stock - Total Liabilities Trend (2015–2025)

This chart illustrates how Amneal Pharmaceuticals, Inc. Class A Common Stock's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see how large is Amneal Pharmaceuticals, Inc. Class A Com's balance sheet.

Amneal Pharmaceuticals, Inc. Class A Common Stock Competitors by Total Liabilities

The table below lists competitors of Amneal Pharmaceuticals, Inc. Class A Common Stock ranked by their total liabilities.

Company	Country	Total Liabilities
Amdocs Limited F:AOS	Germany	€2.88 Billion
Novoray Corporation SHG:688300	China	CN¥585.16 Million
Axfood AB ST:AXFO	Sweden	Skr29.08 Billion
Reinet Investments S.C.A AS:REINA	Netherlands	€2.00 Million
Hancock Whitney Corp NASDAQ:HWC	USA	$31.90 Billion
Porto Seguro S.A SA:PSSA3	Brazil	R$41.80 Billion
Isupetasys KO:007660	Korea	₩606.96 Billion

Liability Composition Analysis (2015–2025)

This chart breaks down Amneal Pharmaceuticals, Inc. Class A Common Stock's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See how leveraged is Amneal Pharmaceuticals, Inc. Class A Com's balance sheet to measure how much of total assets are equity-financed.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric	Value	Description
Current Ratio	2.20	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	N/A	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	110.81	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	0.97	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Amneal Pharmaceuticals, Inc. Class A Common Stock's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Amneal Pharmaceuticals, Inc. Class A Common Stock (2015–2025)

The table below shows the annual total liabilities of Amneal Pharmaceuticals, Inc. Class A Common Stock from 2015 to 2025.

Year	Total Liabilities	Change
2025-12-31	$3.67 Billion	+3.56%
2024-12-31	$3.55 Billion	+3.95%
2023-12-31	$3.41 Billion	-4.99%
2022-12-31	$3.59 Billion	+0.50%
2021-12-31	$3.57 Billion	-2.10%
2020-12-31	$3.65 Billion	+9.95%
2019-12-31	$3.32 Billion	-3.97%
2018-12-31	$3.46 Billion	+101.25%
2017-12-31	$1.72 Billion	+23.14%
2016-12-31	$1.39 Billion	+16.14%
2015-12-31	$1.20 Billion	--

About Amneal Pharmaceuticals, Inc. Class A Common Stock

NASDAQ:AMRX USA Drug Manufacturers - Specialty & Generic

Market Cap

$6.89 Billion

Market Cap Rank

#3185 Global

#1121 in USA

Share Price

$19.77

Change (1 day)

-0.18%

52-Week Range

$11.81 - $20.16

All Time High

$20.16